Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Nuvo Research collaborates with Ferndale to develop 2 topical dermatology products

Nuvo Research collaborates with Ferndale to develop 2 topical dermatology products

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced a collaboration involving Ferndale Laboratories, Inc. and a leading Contract Research Organization with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer technology. [More]

Uncontrollable sweating of hyperhidrosis can have serious impact on person

Sweating is a natural function of the body to cool it down during physical exertion or from a warm environment or to even help cope with emotional situations. [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]

Allergan notes public filings made by Pershing Square and Valeant Pharmaceuticals

Allergan, Inc. ("Allergan" or the "Company") today became aware of public filings made by Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") regarding Valeant's purported intention to propose a merger in which the Company's stockholders would receive a combination of Valeant common shares and cash in exchange for the outstanding shares of the Company's common stock. [More]
Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Research roundup: Colonscopy in the countryside; retiree health benefits; what should hip surgery cost?

Rural residents who commonly seek treatment for advanced stages of colorectal cancer have been thought to lack access to cancer screening and adjuvant therapy. ... Several theories have been postulated to explain these findings, some of which include low socioeconomic status, lower educational attainment, lack of insurance coverage, underinsurance, and travel distance to health care facilities. [More]
FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis plc and Forest Laboratories, Inc. today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. [More]

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development [More]

Free medication samples in dermatology offices appear to change prescribing practices for acne

The availability of free medication samples in dermatology offices appears to change prescribing practices for acne, a common condition for which free samples are often available. [More]

New initiative aims to develop Global Psoriasis Atlas

While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization, reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6% . [More]
Penn Medicine to host symposium on regenerative medicine

Penn Medicine to host symposium on regenerative medicine

The University of Pennsylvania's Institute for Regenerative Medicine will host a symposium on Friday, April 11, 2014 to detail the progress researchers are making toward reprogramming human cells to treat a variety of diseases. [More]

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Forest Laboratories, Inc. and Almirall, S.A. today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol. [More]

Chromogenex launches non-surgical fat reduction and body shaping system

Chromogenex, a world leader in laser innovation, announced today the launch of i-LipoXcell, the company's non-surgical fat reduction and body shaping system. Representing third generation technology, i-LipoXcell incorporates both visible red and infrared lasers for bio-stimulation of metabolic pathways, effectively shrinking fat cells through the release of fatty acids and glycerol. [More]

Meda reaches agreement with Valeant to terminate joint ventures

Meda has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates have been established. [More]

Syneron's Sublative technology receives CE Mark for effective treatment of striae, acne scars

Syneron Medical Ltd., a leading global aesthetic device company, announced today that its proprietary Sublative™ technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars. [More]

Actavis opens new regional headquarters in Singapore

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. [More]
New research suggests why vitamin D deficiency screening tests have gained more importance

New research suggests why vitamin D deficiency screening tests have gained more importance

New research from Wake Forest Baptist Medical Center suggests that physicians are ordering vitamin D deficiency screening tests for preventive care purposes rather than after patients develop conditions caused by decreased bone density. [More]
Protein that activates hair follicle growth inhibits fat production

Protein that activates hair follicle growth inhibits fat production

In particular, the protein that activated hair follicle growth was shown to also inhibit fat production. [More]

iPhone app uses science to help people with acne make better food choices

​Acne sufferers around the world are using an iPhone app created at Northwestern University to learn how certain foods affect their skin conditions. [More]
Molecular function of "hairless" gene may contribute to pathogenesis of atrichia with papular lesions

Molecular function of "hairless" gene may contribute to pathogenesis of atrichia with papular lesions

It's not a hair-brained idea: A new research report appearing in the April 2014 issue of The FASEB Journal explains why people with a rare balding condition called "atrichia with papular lesions" lose their hair, and it identifies a strategy for reversing this hair loss. [More]
Actavis announces acquisition of Silom Medical for $100 million

Actavis announces acquisition of Silom Medical for $100 million

Actavis plc, a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. [More]